DOC1021
Phase 2Biologic
DOC1021 is one of 7 biologic programs targeting Refractory Melanoma. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
7 competitors in Glioblastoma (GBM)
#DrugCompanyPhaseTrials
1Temodar
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2
Keytruda
Merck & Co.Preclinical
Yervoy
Bristol-Myers SquibbPreclinical
DOC1021
DDiakonos Oncology Corporation
Phase 2
Temodar
DDiakonos Oncology Corporation
Phase 2
BGB-58067
BBeOne Medicines
Phase 1
Breakvax
BBreakBio Corp
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DOC1021. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- DDiakonos Oncology Corporation